On October 10th, Sarah Brooks
, a shareholder in Stradling's Intellectual Property practice group, spoke with the Daily Journal
for an article on regarding a U.S. Senator’s introduction of legislation intended to block Allergan
’s transfer of its eye medication RESTASIS patents to the Saint Regis Mohawk tribe.
, a shareholder in Stradling’s Intellectual Property Litigation
practice, provided commentary to the Pink Sheet
on Allergan’s transfer of patents for RESTASIS to the Saint Regis Mohawk Tribe, The creative agreement gives the tribe exclusive commercial rights to these patents to avoid the inter partes review (IPR) process.